MA
JAZZ icon

MANA Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

MANA Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,634
Closed -$234K – 194
2019
Q1 		$234K Buy
+1,634
New +$213K 0.76% 71
2018
Q4 		– Sell
-1,861
Closed -$313K – 97
2018
Q3 		$313K Buy
+1,861
New +$320K 1.42% 17

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

MANA Advisors's JAZZ Position: Q2 2019 in Review

MANA Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2019, closing a stake of 1,634 shares — an estimated $234K sold.

MANA Advisors first reported a position in JAZZ in Q3 2018 and held it in 2 quarters. The position peaked at $313K in Q3 2018. 416 funds tracked by Wall St. Rank hold JAZZ as of Q2 2019.

  • MANA Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • MANA Advisors sold 1,634 Jazz Pharmaceuticals shares in Q2 2019, an estimated $234K.
  • MANA Advisors first reported a position in Jazz Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • MANA Advisors's Jazz Pharmaceuticals position peaked at $313K in Q3 2018.
  • 416 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2019.

Based on MANA Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.